Two podium and one poster presentation share important new findings on FINTEPLA’s safety profile and its impact on non-seizure related benefits for LGS...
Total revenue of $26.6 million in the fourth quarter and $81.7 million for the full yearFINTEPLA® net product sales of $23.5 million in the fourth quarter...
Symptoms of mitochondrial diseases, such as Thymidine Kinase 2 deficiency (TK2d), can vary widely and mimic other rare and common diseases, making...
The company attracts a determined suitor from abroad.
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Zogenix, Inc. (NASDAQ: ZGNX) to UCB is fair to Zogenix shareholders. Under the terms of the agreement, UCB would...
A buyout deal is lighting a fire underneath the biotech's shares today.
Morning Markets March S&P 500 futures this morning recovered from a 4-week low in overnight trade and are up +0.40%. Optimism about Q4 corporate earnings results is helping to push stocks higher this...
EMERYVILLE, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Zogenix, a global biopharmaceutical company specializing in rare disease therapies, announced that...
EMERYVILLE, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare...
EMERYVILLE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company’s board of...